First patient in China dosed with subcutaneous auto-injector lecanemab for Alzheimer’s disease — available first in Lecheng阿尔茨海默病新药仑卡奈单抗皮下自动注射剂型在乐城可及，国内首位患者完成用药

On 22 October 2026, a 73-year-old patient became the first person in China to receive the new subcutaneous auto-injector formulation of lecanemab, at Ruijin Hospital Hainan in Lecheng. The formulation — approved by China's NMPA — offers a portable, flexible option for Alzheimer's patients, and Lecheng's 'first access' policy made it available here before it was broadly available elsewhere in the country.

2026年10月22日，73岁的葛女士在乐城瑞金海南医院完成仑卡奈单抗皮下自动注射剂型首次给药，成为国内首位接受该剂型治疗的患者。该剂型已获 NMPA 批准，为需要便携、灵活用药方案的患者提供了新选择，乐城“先行先试”政策让它率先可及。

This page is a short English/Chinese summary of the facts in a patient story published by the Lecheng Administration. Photos are from that publication, credited; a link to the original Chinese article sits at the foot of this page. 本页是对Lecheng Administration发布的一篇患者故事中事实的简短中英摘要。照片取自该发布并标注来源；官方中文原文链接见本页页脚。